今日药学

2021, v.31(05) 392-395

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

1例信迪利单抗致免疫相关性胰腺炎的药学监护实践
Practice of Pharmaceutical Care in Immune-associated Pancreatitis Caused by Sintilimab by Clinical Pharmacists

周花萍;陈永;
ZHOU Huaping;CHEN Yong;Guangzhou 8th People's Hospital;The First Affiliated Hospital of Guangdong Pharmaceutical University;

摘要(Abstract):

目的探讨临床药师如何对PD-1致免疫相关性胰腺炎患者实施药学监护。方法以1例非小细胞肺癌患者使用PD-1导致免疫相关性胰腺炎为例,协助治疗团队判定是否为免疫相关性胰腺炎及其严重程度,协助制定以糖皮质激素治疗为主的治疗方案。结果在临床药师与治疗团队的密切配合下,患者获得了较为完善的药物治疗方案与药学监护,使免疫相关性胰腺炎指标趋于正常,临床症状改善。结论临床药师介入免疫相关性胰腺炎的药物治疗,使临床用药更趋合理,有利于提高临床药物治疗水平和疾病治疗的有效率。
OBJECTIVE To explore the pharmaceutical care for PD-1-induced pancreatitis performed by clinical pharmacists. METHODS The pharmacist assisted the treatment team to determine whether it was immune-related pancreatitis caused by sintilimab in a non small cell lung cancer patient and its severity, formulated a treatment plan based on glucocorticoid. RESULTS The patient's clinical symptoms and immune-related pancreatitis indicators had been improved after the clinical pharmacist and the treatment team formulating a good treatment plan and pharmaceutical care plan. CONCLUSION Clinical pharmacists participate in medical treatment of immune-associated pancreatitis, which can make clinical medication more rational and help to improve the treatment effect.

关键词(KeyWords): 免疫相关性胰腺炎;信迪利单抗;糖皮质激素;药品不良反应;临床药师
immune-associated pancreatitis;sintilimab;glucocorticoid;adverse drug reaction;clinical pharmacists

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 周花萍;陈永;
ZHOU Huaping;CHEN Yong;Guangzhou 8th People's Hospital;The First Affiliated Hospital of Guangdong Pharmaceutical University;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享